Senti Biosciences Holdings Inc. (SNTI)
SNTI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/0001628280-26-021580-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SNTI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001854270 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $22K |
| Net income | -$61.4M |
| Operating income | -$68.8M |
| Net margin | -279263.6% |
| Operating margin | -312631.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $16.4M |
| Total assets | $51.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 237.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Notes to Condensed Consolidated Financial Statements (Continued) (Unaudited) the Company's liquidity, the Company concluded that substantial doubt continued to exist and that the Company's cash and cash equivalents of $ 6.5 million as of June 30, 2026, were not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these condensed consolidated financial statements." | 10-Q 2026-08-14 |
| Cash and burn | $6.5M cash; operating cash flow -$9.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 31,144,754 (2026-07-31); 26,160,206 a year earlier; 44,545,186 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-07-31 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-07-18 | Source 2024-07-18 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-05-01 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-09-02 |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $17K | -$12.8M | -$14.2M | $6.5M | $4.0M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $16K | -$4.2M | -$7.5M | $8.9M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$14.5M | -$6.9M | $16.4M | $0 | $22K | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | Not filed | -$18.1M | -$9.4M | $12.2M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $0 | -$14.7M | -$13.1M | $21.6M | No debt tags | $0 | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$14.1M | -$14.1M | $33.8M | No debt tags | $0 | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $0 | -$610K | -$13.5M | $48.3M | No debt tags | $0 | 10-K 2025-03-20 |
| Q3 2024 2024-09-30 | $0 | -$28.9M | -$7.9M | $10.5M | No debt tags | $0 | 10-Q 2024-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.5% |
| 1 month | -45.1% |
| 3 months | -63.5% |
| Year to date | -86.5% |
| 1 year | -92.2% |
| From 52-week high | -94.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| CRIS | Curis Inc. | $0.4358 | -2.07% | $4.1M |
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
| TCRX | TScan Therapeutics Inc. | $0.1451 | -9.65% | $9.2M |
| INTS | Intensity Therapeutics Inc. | $3.07 | -0.32% | $10.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier